Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Hemogenyx Pharmaceuticals Plc HEMO.L
$2.23
+$0.1 (4.71%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
24267500.00000000
-
week52high
4.30
-
week52low
1.15
-
Revenue
0
-
P/E TTM
0
-
Beta
3.69274800
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 апр 2023 г. в 06:00
Описание компании
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии